

Natural Killer Cell Transfer Assay

Lee-Hwa Tai¹, Christiano Tanese de Souza¹, Andrew P. Makrigiannis² and Rebecca Ann C. Auer^{3*}

¹Centre for Innovative Cancer Research, Ottawa Hospital Research Institute, Ottawa, Canada;

²Biochemistry, Microbiology and Immunology Department, University of Ottawa, Ottawa, Canada;

³Department of Surgery, University of Ottawa, Ottawa, Canada

*For correspondence: rauer@ottawahospital.on.ca

[Abstract] Natural Killer (NK) cells are cytotoxic lymphocytes that constitute a major component of the innate immune system. Immunosurveillance of the host by NK cells for malignant and virally-infected cells results in direct cytotoxicity and the production of cytokines to enhance the immune response. This protocol will describe the adoptive transfer of purified NK cells into NK cell-deficient tumor bearing mice in order to establish the intrinsic functionality of NK cells.

Materials and Reagents

1. Lympholyte-M (Cedarlane, catalog number: CL5035)
2. Source of mouse NK cells: C57Bl/6 mice (Charles Rivers, strain code: 027)
3. NK-deficient mice (Jackson Labs, strain name: B6.129S4-Il2rg^{tm1Wjl}/J, strain number: 003174)
4. Gluteraldehyde
5. Potassium ferrocyanide
6. Potassium ferricyanide
7. Bovine serum albumin (BSA)
8. 100x Non-essential amino acids
9. Fetal bovine serum (FBS)
10. Sodium pyruvate
11. Deoxycholate
12. B16F10lacZ melanoma tumor cells, grown in complete DMEM (Dr. K. Graham, London Regional Health Centre, London ON)
13. 1x sterile PBS (Hyclone, catalog number: 21-031-CV)
14. X gal (Bioshop Canada Inc., catalog number: XGA001-1)
15. Running buffer (Miltenyi Biotech, catalog number: 130-091-221)
16. Washing buffer (Miltenyi Biotech, catalog number: 130-092-987)
17. AutoMACS pro columns (Miltenyi Biotech, catalog number: 130-021-101)

18. RPMI 1640 (Hyclone, catalog number: SH300027.01)
19. AutoMACS buffer (see Recipes)
20. Complete RPMI (see Recipes)
21. NK cell media (see Recipes)
22. LacZ staining solutions (see Recipes)

Equipment

1. 50 ml tubes (BD Biosciences, Falcon®, catalog number: 352098)
2. 15 ml tubes (BD Biosciences, Falcon®, catalog number: 352096)
3. Insulin syringe 27G1/2" (Terumo Medical Corporation, catalog number: SS05M2713)
4. AutomacsPro Separator (Miltenyi biotech, model: 130-092-545)
5. Incubator (5% CO₂, 37 °C) (Sanyo)
6. Centrifuge (when parameters of brakes are unspecified, maximal acceleration and deceleration are used), (Thermo Fisher Scientific, model: ST40R)
7. Dissection instruments (small forceps, scissors)
8. Light microscope (Leica)
9. Cell strainers 70 µm (Thermo Fisher Scientific, catalog number: 22363548)
10. DX5 (CD49b) microbeads (Miltenyi Biotech, catalog number: 130-052-501)

Procedure

- A. Treatment of donor mice – mouse model of surgical stress
 1. Donor mice (6-8 weeks of age, each weighing approximately 20 g) were treated with abdominal left nephrectomy (surgical stress) 18 h prior to harvesting spleen NK cells for transfer into recipient mice.
 2. 3 C57Bl/6 mice are usually sufficient in order to get 2.0×10^6 NK cells. However, for any *in vivo* treatment (*i.e. in vivo* virus infection) that might result in lymphopenia or lymphocyte migration to the periphery, more mice may be needed.
 3. Prepare dissection instruments for harvesting splenocytes.
- B. Harvest donor splenocytes
 1. 1 h before starting the harvest, remove Lympholyte from 4 °C. Lympholyte needs to be used at room temperature and protected for light (handle under biosafety cabinet with lights off).

2. Prepare one 50 ml tube and two 15 ml tubes for each spleen. Place a 70 μ M cell strainer on each opened 50 ml tube. Prime each strainer with 1 ml of cold 1x PBS. Add 5 ml of Lympholyte into each 15 ml tube (protect tubes from light).

Note: 1 spleen will need two 15 ml tubes, each containing 5 ml Lympholyte.

3. Euthanize mice by cervical dislocation, remove spleen and place on 70 μ M strainer
4. Crush 1 spleen on a 70 μ M cell strainer over a 50 ml tube, rinse twice with 10 ml of 1x PBS (I often rinse the underside of the filters as well if visible clumps of spleen are observed). Filter again with 10 ml of 1x PBS using the same filter if needed. Spin at 500 x g, 5 min, 4 °C.
5. Discard supernatant and resuspend splenocyte pellet in 10 ml 1x PBS. Carefully layer 5 ml of resuspended splenocytes on top of the Lympholyte layer (5 ml of the 1st 15 ml tubes, then the remaining 5 ml on the 2nd 15 ml tube). Spin 1,500 x g, 15 min, room temperature, acceleration at 1, deceleration at 2 (minimal speed).
6. Carefully pipet lymphocyte layer (blurry interface layer between Lympholyte at the bottom and PBS on top) and transfer to a new 50 ml tube. You can combine mice treatments here (e.g. all the same treatments together).
7. Fill 50 ml tube with 1x PBS (first wash to remove excess Lympholyte). Spin down 500 x g, 5 min, 4 °C.
8. Discard supernatant. Resuspend pellet in 10 ml AutoMACS buffer. Spin down as in step B-7. Discard supernatant.

C. NK cell sort (with DX5 microbeads)

1. Resuspend splenocytes pellet in 300 μ l AutoMACS buffer per spleen (We usually pool 3 spleens per tube).
2. Add 100 μ l of DX5 microbeads per spleen (manufacturer recommends 100 μ l beads volume for 1×10^8 or less cells) and mix well. Incubate for 15 min at 4 °C.
3. Add 10 ml of AutoMACS buffer to stop DX5 incubation. Spin as in step B-7.
4. Discard supernatant. Resuspend pellet in 500 μ l AutoMACS buffer per spleen (e.g. 1.5 ml for 3 pool spleens).
5. Proceed to sort. Turn AutoMACS Pro sorter on during last spin and do a rinse before starting.
6. Place tubes (input in A, negative fraction in B, positive fraction in C) in rack holder. The size of the tubes used for sort depends on the AutoMACS rack holder used. Usually a standard 50 ml tube for the 3 holder rack, 15 ml tube for 5 holder rack, and 5 ml flow cytometry tubes for 6 holder rack. "Negative fraction" denotes the eluate after the sort, which contains DX5⁻ non-NK cells. "Positive fraction" denotes the eluate after the sort, which contains DX5⁺ NK cells.

7. Select program: Possel with a quick rinse (qrinse) between each tube and rinse after the last tube. Start the sort.
8. After the sort, count the number of DX5⁺ cells in the positive fraction tube (2 ml total volume) and determine the cell concentration. Spin down. NK cell purity as determined by flow cytometry (DX5⁺, TCRb⁻) is usually > 90%.

D. NK cell transfer and tumor injection

1. Resuspend 1.0×10^6 DX5⁺ NK cells in sterile 1x PBS cells and inject via tail vein injection (100 μ l total volume) into NK-deficient mice.
2. 1 h post NK cell injection, 3×10^5 B16lacZ tumor cells resuspended in 100 μ l serum free DMEM (greater than 90% viability as determined by trypan blue), inject via tail vein injection (100 μ l total volume) into the same NK-deficient mice.

Note: For mouse model of surgical stress experiments, recipient NK-deficient mice received NK cells from surgically stressed and untreated control donor mice.

3. Allow mice to survive for 3 days post tumor cell injection.

E. B16lacZ lung tumor quantification

1. 3 days post NK and tumor cell injection, euthanize recipient mice and extract all 5 lobes of the lungs.
2. To extract lungs, expose the thorax by cutting through the skin and subcutaneous layer along the ventral midline of the chest cavity of the mouse. Next, make lateral incisions through skin and tissue on each side up to the neck of the mouse. Then, gently grasp lungs with surgical forceps and gently dissected by snipping away the connective tissue above and below the lungs.
3. Rinse lungs in Phosphate buffer (pH 7.3).
4. Place lungs into scintillating vial containing 5 ml ice-cold Phosphate buffer (pH 7.3). Keep on ice until next step.
5. Pour out Phosphate buffer, being careful not to lose lungs. Fix lungs for 20 min by adding in fixative solution (8 ml/vial).
6. Wash twice for 10 min in wash buffer solution (8 ml/vial).
7. Stain with X gal overnight at 37 °C (12-18 h–2 ml/vial).
8. Wash once with wash buffer (5 ml/vial for 10 min), then add fresh wash buffer (10 ml/vial) and store at 4 °C overnight. Staining will intensify.
9. Aspirate wash buffer and add 15 ml/vial of 10% buffered Formalin for preservation.
10. Quantify lung metastases with light microscope.
11. See Figure 1: Representative lung picture depicting B16lacZ lung metastases at day 3 post tumor cell intravenous injection is shown.



Figure 1. Representative lung pictures showing B16lacZ lung tumor metastases at day 3 post-tumor cell intravenous injection

Recipes

1. Automacs buffer in 500 ml
 - PBS
 - 2.5 g Bovine Serum Albumin
 - 2 ml of 5 mM EDTA
2. Complete RPMI in 500 ml
 - 500 ml of RPMI-1640
 - 50 ml Heat-inactivated Fetal Bovine Serum
 - 5 ml of Pencillin-Streptomycin 10,000 U each/ml
3. NK cell media
 - 500 ml of cRPMI
 - 5 ml 1 M HEPES
 - 5 ml 100 mM Sodium Pyruvate
 - 5 ml 100x Non-Essential Amino Acids
 - 0.5 ml of 2-mercaptoethanol for final concentration of 5×10^{-5} M
4. LacZ staining working solutions
 - a. 0.1 M Phosphate buffer in 5 L at pH 7.3
 - 15.87 g Sodium Phosphate Monobasic (MW 137.99)
 - 54.67 g Sodium Phosphate Dibasic (MW 141.96)
 - Dissolve into 5 L of dH₂O
 - b. Fixative solution in 900 ml
 - 45 ml 100 mM EGTA (pH 7.3)
 - 1.8 ml 1 M Magnesium Chloride

846 ml 0.1 M Phosphate buffer (pH 7.3)

Prepare the stock solution without gluteraldehyde

Aliquot 1.8 ml of 25% gluteraldehyde into 223.3 ml of stock when you are ready to use

This will allow you to prepare 225 ml of fresh fixative solution.

c. Wash buffer in 3.6 L

7.2 ml 1 M Magnesium Chloride

36 ml 1% Deoxycholate

36 ml 2% Nonidet-P40

3,520.8 ml 0.1 M Phosphate buffer (pH 7.3)

d. 25 mg/ml X gal stock

1 g of X gal in 40 ml of DMSO

e. X gal stain in 1 L

40 ml of 25 mg/ml X gal stock

2.12 g Potassium Ferrocyanide (MW 422.2)

1.64 g Potassium Ferricyanide (MW 329.2)

960 ml Wash buffer

Acknowledgments

This protocol was adapted from the following paper: Kirstein *et al.* (2009). This study was supported by Canadian Cancer Society Research Institute, Ontario Regional Biotherapeutics (ORBiT) program, Private Donor (D.H.) Ottawa Hospital Foundation, (R.A. Auer) and Fonds de Recherche Sante Quebec (L.-H. Tai and S. Belanger).

References

1. Kirstein, J. M., Graham, K. C., Mackenzie, L. T., Johnston, D. E., Martin, L. J., Tuck, A. B., MacDonald, I. C. and Chambers, A. F. (2009). [Effect of anti-fibrinolytic therapy on experimental melanoma metastasis](#). *Clin Exp Metastasis* 26(2): 121-131.